Related Experiment Videos
Combination antiemetics for cisplatin chemotherapy
1Papanicolaou Comprehensive Cancer Center, Department of Oncology, University of Miami School of Medicine, Jackson Memorial Hospital, FL 33101.
Cancer
|April 15, 1988
Summary
A combination of four antiemetics effectively prevents nausea and vomiting in patients undergoing cisplatin chemotherapy. This treatment offers significant protection with minimal side effects, improving patient tolerance to chemotherapy.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Cisplatin chemotherapy frequently causes nausea and vomiting, significantly impacting patient quality of life.
- Standard single-agent antiemetic therapy often proves insufficient for managing chemotherapy-induced nausea and vomiting (CINV).
Purpose of the Study:
- To evaluate the efficacy and toxicity of a combination antiemetic regimen for preventing nausea and vomiting in patients receiving cisplatin chemotherapy.
Main Methods:
- A combination of metoclopramide, diphenhydramine, droperidol, and dexamethasone was administered prophylactically to 67 patients undergoing cisplatin chemotherapy.
- Patient outcomes, including complete protection from nausea and vomiting, incidence of nausea/vomiting, and toxicities, were assessed over multiple treatment courses.
Main Results:
- 76.1% of patients achieved complete protection from nausea and vomiting in the first course; 62.7% in all courses.
- 73.3% of evaluable courses had no nausea or vomiting, and 79.5% had no vomiting.
- Mild and infrequent toxicities were observed, with reversible extrapyramidal reactions occurring in 5.6% of courses.
Conclusions:
- The combination of metoclopramide, diphenhydramine, droperidol, and dexamethasone is highly effective in preventing cisplatin-induced nausea and vomiting.
- This multi-agent antiemetic approach demonstrates good tolerability and minimal toxicity, enhancing patient management during chemotherapy.